Norgine’s NPJ5008 (Dantrolene sodium hemiheptahydrate) Receives CHMP’s Positive Opinion for the Treatment of Malignant Hyperthermia
Shots:
-
Norgine received a positive CHMP opinion for NPJ5008 (Dantrolene sodium hemiheptahydrate) for the treatment of Malignant Hyperthermia
-
With NPJ5008, dantrolene is prepared and administered quickly using novel formulation vs. Dantrolene IV (dantrolene sodium). NPJ5008 (IV) contains 120 mg of dantrolene in each vial and is reconstituted in 20 mL of water
-
For its final decision, the EC will refer to NPJ5008's positive opinion grant by the CHMP. NPJ5008’s UK (MHRA) & Switzerland (Swiss Medic) submission is ongoing
Ref: Norgine | Image: Norgine
Related News:- Fennec Pharmaceuticals and Norgine Collaborate for the Commercialization of Pedmarqsi in the EU, Australia and New Zealand
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
